Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognoses with respect to mortality and hepatic and nonhepatic outcomes across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well defined. METHODS: We prospectively followed a multicenter patient population that included the full histologic spectrum of NAFLD. The incidences of death and other outcomes were compared across baseline histologic characteristics. RESULTS: A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 person-years for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 person-years for stage F4 [cirrhosis]). The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14). As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages. After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3). CONCLUSIONS: In this prospective study involving patients with NAFLD, fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; NAFLD DB2 ClinicalTrials.gov number, NCT01030484.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The risk of future liver-related events starts to increase at fi brosis stage 2.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [122]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“fibrosis stage is predictive of liver-specific morbidity and mortality.”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Ultimately, those with NASH and fibrosis may develop end-stage complications such as cirrhosis, portal hypertension or hepatocellular carcinoma (HCC), which portend a much worse prognosis.6–10”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
In the citing paper
“In patients with MASLD, liver fibrosis represents the primary determinant of mortality [258–261].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [261]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationA Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citation
Cited by
Items 701–800 of 1,001
Sohal, A., Wilson, L. A., Kleiner, D. E., Loomba, R. S., Yuan, L., Dasarathy, S., Sanyal, A. J., Neuschwander‐Tetri, B. A., Chalasani, N., Diehl, A. M., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000847 · Cited by 6
Self-citationFIB‐4 Serves as a Referral Index for Coronary Artery Calcification in Patients With MASLD
Huang, Y., Wang, C., Huang, J., Liang, P., Yeh, M., Chen, Y., Lin, Y., Jang, T., Wei, Y., Hsieh, M., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70162 · Cited by 4
“While traditional cardiovascular risk factors, such as hypertension, diabetes, and dyslipidemia, are known contributors to CAC development, recent studies have highlighted the potential role of liver disease, particularly liver fibrosis, in cardiovascular risk [11–13].”
Viceconti, N., Andaloro, S., Paratore, M., Miliani, S., Giulia, D., Cerniglia, G., Mancuso, F., Melita, E., Gasbarrini, A., Riccardi, L., et al. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i2.113059 · Cited by 4
p16 Ink4a ‐Positive Hepatocytes Drive Liver Fibrosis Through Activation of LIFR Family Pathway
Nishikawa, K., Wang, T., Kawakami, S., Tanimoto, S., Yamaguchi, K., Kido, T., Kimura, M., Hishima, T., Okamura, Y. T., Omori, S., et al. (2026) · Advanced Science · doi:10.1002/advs.202510562 · Cited by 5
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Abreu, E. S., Noureddin, M., Takahashi, H., Schattenberg, J. M., & Abdelmalek, M. F. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.004 · Cited by 4
Cardiovascular-Kidney-Metabolic Syndrome: Development of an ICD-10-CM Coding Framework
ZHAO, M., Zhang, J., Wang, H., Xu, C., Li, J., Li, C., He, X., & Zheng, X. (2026) · JMIR Diabetes · doi:10.2196/91827 · Cited by 5
“The presence of NASH indicates that the body has a greater amount of metabolic dysfunction than is seen with other forms of fatty liver disease and has a greater chance of developing systemic problems related to that severity of metabolic dysfunction [71,74].”
Albusta, N., Isa, S., & Alrahma, H. N. S. (2026) · Diseases · doi:10.3390/diseases14050173 · Cited by 8
“Consequently, lean patients may escape detection until advanced disease stages when symptoms of portal hypertension, hepatic decompensation, or HCC prompt evaluation [55].”
Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options
Ren, R., Liang, X., & Wei, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00486-5 · Cited by 6
“However, once cirrhosis develops, liver-related mortality, including deaths from complications of cirrhosis and hepato-cellular carcinoma (HCC), rises substantially [20, 21].”
Diambra, L. A., Sookoian, S. C., & Pirola, C. J. (2026) · Gut · doi:10.1136/gutjnl-2026-338674 · Cited by 5
Wei, S., He, Y., Luo, C., & He, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1924392 · Cited by 4
“…and meta-analyses consistently demonstrate that fi brosis stage — rather than steatosis alone or NAFLD activity score — is the strongest predictor of all-cause and liver-related mortality (128 – 132), and activation of the NLRP3 in fl ammasome plays an indispensable role in the fi brotic process.”
Gee, M. F. W., Chalfin, D. B., Devol, E. B., Levy, H. R., Boltyenkov, A., Casale, M. G., & Sanyal, A. J. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70846 · Cited by 5
“Notably, prior studies have shown that patients with ELF scores 9.00 are unlikely to progress to cirrhosis within 1 year or to experience liver-related clinical outcomes within 2–5 years [79–81], consistent with outcomes observed in patients with histologically confirmed fibrosis F2 [82].”
InfluentialSelf-citationRomero‐Gómez, M. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2022.09.004 · Cited by 13
Pagé, G., Juléa, F., Paradis, V., Vilgrain, V., Valla, D. C., BEERS, B. E. V., & Garteiser, P. (2022) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28543 · Cited by 4
“MARS algorithm provided stiffness values significantly higher than MDEV values at 40 Hz for fibrosis score F1, F3, and F4, at 60 Hz for F0, F1, F2, F3, and F4 and at 80 Hz for F0, F1, F2, and F4.”
MethodScreening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
Kasper, P., Demir, M., & Steffen, H. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0059 · Cited by 4
NAFLD and liver-related events: does type 2 diabetes have a key role?
Gómez, E. V. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00187-5 · Cited by 4
Gentilucci, U. V., Valenti, L. V. C., & Romeo, S. (2023) · Liver International · doi:10.1111/liv.15697 · Cited by 4
Nomoto, H., Kito, K., Iesaka, H., Handa, T., Yanagiya, S., Miya, A., Kameda, H., Cho, K. Y., Takeuchi, J., Nagai, S., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01187-7 · Cited by 5
“Conversely, subjects with progressive liver fibrosis have a higher incidence of T2D [3], indicative of a close relationship between T2D and MAFLD.”
BackgroundImpact of peripheral thyroid hormone balance on liver fat: insights from the NutriAct trial
Sommer, M., Nguyen, T.-H., Pletsch‐Borba, L., Wernicke, C., Tacke, F., Schwerdtle, T., Pellowski, D., Machann, J., Spranger, J., Wirth, E. K., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae093 · Cited by 6
Liver Transplantation: A Test of Cellular Physiology, Preservation, and Injury
Martins, B., Mossemann, J., Aguilar, F., Zhao, S., Bilan, P. J., & Sayed, B. A. (2024) · Physiology · doi:10.1152/physiol.00020.2024 · Cited by 5
Vaz, K., Kemp, W. W., Majeed, A., Lubel, J. S., Magliano, D. J., Glenister, K., Bourke, L., Simmons, D. S., & Roberts, S. K. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16774 · Cited by 5
“6,7 The past decade has witnessed a boom in the development of non-invasive tests (NITs) of liver fi brosis that aim to be accurate surrogates for the imperfect invasive “ gold standard ” method of liver biopsy.”
Systems of care that improve outcomes for people with hepatic encephalopathy
de León, I. H.-D., & Tapper, E. B. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01430-8 · Cited by 5
Sun, N. Z., Prescott, B. R., Ma, J., Xanthakis, V., Quatromoni, P. A., Long, M. T., & Walker, M. E. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.01.045 · Cited by 5
Wang, C., Hongfei, M., Yang, H., Nie, Q., Zhu, L., Yin, J., & Zhou, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-04121-1 · Cited by 4
“Third, because liver fibrosis stage is associated with increased mortality 34 we further adjusted for the fibrosis-4 index score (FIB-4) based on model 3.”
Desjonqueres, E., & Gigante, E. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2021.136 · Cited by 4
Saleh, Z. M., & Tapper, E. B. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01112-3 · Cited by 4
“(Sanyal et al. 2021) Given the gravity of HE and its associated downstream complications, developing a reliable predictive model is key.”
BackgroundXiang, X., Bhowmick, K., Shetty, K., Ohshiro, K., Yang, X., Wong, L. L., Yu, H., Latham, P. S., Satapathy, S. K., Brennan, C., et al. (2024) · Genes & Cancer · doi:10.18632/genesandcancer.234 · Cited by 4
“…and surveillance strategies that reflect pathology in the continuum of liver disease from cirrhosis to HCC. Molecular heterogeneity, multiple etiologies, and divergent pathophysiology associated with HCC have delineated molecular pathways that control the initiation and progression of HCC [9–11].”
BackgroundSelf-citationYilmaz, Y. N. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18171 · Cited by 4
“2,3 However, the study could”
Jasty, V. S. J., Urias, E., Tiong, K. L. A., Aboona, M. B., Song, M. W., Faulkner, C., Devan, P., Neo, J. E., Wijarnpreecha, K., Wong, Y. J., et al. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08635-y · Cited by 5
“…liver decompensation, and with a global prevalence of nearly 30% and still rising, there is an increasing need to accurately identify those who are at high risk for developing major complications while avoiding unnecessary interventions on patients who are very low risk for progressive disease [4].”
Nonalcoholic Fatty Liver Disease
Parthasarathy, G., & Malhi, H. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197679753.003.0034 · Cited by 4
Nonalcoholic Fatty Liver Disease Natural History: Role of Mathematical Modeling
Chhatwal, J., & Tapper, E. B. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.01.041 · Cited by 4
Needle-free Nonalcoholic Fatty Liver Disease Prognostication: Moving One Step Closer
Behari, J. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.07.078 · Cited by 4
A Revisit of the Natural History of Nonalcoholic Fatty Liver Disease
Noureddin, M., & Wong, V. W. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.08.019 · Cited by 4
Optimizing Prediction of Liver Disease Using Machine Learning Algorithms
Rachna, Jain, T., Shandilya, D., & Gagneja, S. (2024) · Wiley eBooks · doi:10.1002/9781394175376.ch10 · Cited by 4
Cardiovascular and hepatic outcomes: prognostic differences across MASLD-MetALD-ALD continuum
Lee, H. A., Kim, G., & Kim, W. (2026) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2026.0367 · Cited by 7
Jayabalan, D., Dhakal, S., Chandra, J., Fasser, D. A., Jeffrey, G. P., Garas, G., Vilar-Gomez, E., Calzadilla-Bertot, L., & Adams, L. A. (2026) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003918 · Cited by 3
Sukaram, T., Maung, S. T., Chongpison, Y., Jaihan, T., Phathong, C., & Chaiteerakij, R. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101753 · Cited by 5
Kjær, M. B., Jørgensen, A. G., Fjelstrup, S., Dupont, D. M., Bus, C., Eriksen, P. L., Thomsen, K. L., Risikesan, J., Nielsen, S., Wernberg, C. W., et al. (2025) · Biomolecules · doi:10.3390/biom15020255 · Cited by 5
“The different degrees of fibrosis were grouped into F0, F1–F2, and F3–F4 because individuals with advanced fibrosis (F3 and F4) have a higher risk of decompensation events, hepatocellular carcinoma (HCC) development, and overall mortality than those with lower fibrosis stages [31,32].”
Swaroop, S., Biswas, S., Mehta, S., Aggarwal, A., Arora, U., Agarwal, S., Chavan, A., Nayak, B., & Shalimar, S. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.102559 · Cited by 3
Subgroups of Steatotic Liver Disease Have Distinct Clinical Phenotypes
Pekarska, K., Burke, L., Rowe, I. A. C., & Parker, R. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.102587 · Cited by 4
Assessment and management of portal hypertension in patients with MASLD: advances and caveats
Rojo, D., Jiménez-Masip, A., Pagès, L., Bañares, J., Sabiote, C., Martínez-Gómez, M., Aceituno, L., Cusidó, M. S., Salcedo-Allende, M. T., Calixto, Z., et al. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2530605 · Cited by 4
“Several studies have specifically investigated this correlation in patients with MASLD (Table 1) [33,34].”
Quantifying fibrosis in inflammatory bowel diseases – contribution of digital pathology
Jerala, M., Chen, L., Drobne, D., Petitjean, M. M., & Zidar, N. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.08.002 · Cited by 4
Masrour, O., Ehrhard, F., Guillaume, M., Boursier, J., Gournay, J., Aziz, K., Schnee, M., Garlantézec, R., de Lédinghen, V., Morçet, J., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101589 · Cited by 3
Isotype-selective roles of hepatic acetyl-CoA carboxylases in a mouse model of fatty liver disease
Beretta, M., Vancuylenburg, C. S., Shrestha, R., Olzomer, E. M., Osborne, B., Zhou, M., Zhang, S., Hargreaves, A., Byrne, F. L., & Hoehn, K. L. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102264 · Cited by 6
“Liver fibrosis is the primary determinant of mortality in patients with MASH [5] due to increased liver-related complications including higher risk of hepatocellular carcinoma [6,7].”
Watabe, H., Miyagaki, T., Nakajima, K., Go, K., Okano, T., & Kadono, T. (2025) · The Journal of Dermatology · doi:10.1111/1346-8138.70047 · Cited by 3
Transparent and dynamic network-based risk assessment for development of hepatic encephalopathy
Wang, Z., Jiang, S., Liu, F., Wang, X., Wang, G., Huang, R., Kong, X., Fei, R., Li, X., Cao, J., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01292-w · Cited by 3
“In our cohort, HE frequently emerges as the fi rst decompensating eventinpatientswithautoimmune, MAFLD, andalcohol-related cirrhosis, a pattern also observed in a dedicated cohort of MAFLD patients 32 .”
Yeo, Y. H., Ho, H. J., Huang, T., Lee, T., Yang, J. D., Cholankeril, G. T., Chen, C., Yang, H.-I., Chen, C., Chang, H.-C., et al. (2026) · Liver Cancer · doi:10.1159/000550360 · Cited by 3
“…this incidence rate is substantially higher than previously reported in biopsy-proven MASLD patients with advanced F3 fibrosis (0.34% annually) [31] and is comparable to that observed in post-SVR hepatitis C patients with F3 fibrosis (0.50% annually) [32], a population in which EASL guidelines…”
InfluentialȚâru, M.-G., Stefanini, B., Boe, M., Capelli, R., Chen, R., Abbati, C., Santangeli, E., Salamone, A., Girolami, F., Tovoli, F., et al. (2026) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s561956 · Cited by 3
“29”
Yu, C., Qiu, C., Zhang, Q., Wang, W., Liu, S., & Jin, Z. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03043-6 · Cited by 5
Rapamycin Reverses the Hepatic Response to Diet‐Induced Metabolic Stress That Is Amplified by Aging
Havas, A. P., Rajesh, A., Lei, X., Proulx, J. M., Miller, K. N., Field, A. E., Davis, A., Teneche, M. G., Gandhi, A., Lee, J., et al. (2026) · Aging Cell · doi:10.1111/acel.70395 · Cited by 3
de Jong, V., Nissen, S. E., Sasiela, W. J., Li, M., Bloedon, L. T., Lincoff, A. M., Nicholls, S. J., Cabezas, M. C., & Grobbee, D. E. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag102 · Cited by 3
Venkatesh, S. K. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2636184 · Cited by 3
“The incidence of HCC varies from 0.04 in earlier-stage fibrosis (F0−F2) to 0.34 per 100 person-years in patients with advanced fibrosis (≥F3) [113].”
InfluentialKanamoto, A., Miyake, T., Furukawa, S., Yoshida, O., Horiuchi, K., 村上, 善., Miyazaki, M., Nakaguchi, H., Yano, R., Okazaki, Y., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70159 · Cited by 3
Henze, J., Dormann, H., Schneider, C. V., Meeßen, C., Knüppel-Ruppert, A., Kriegisch‐Stumpf, A., Schwab, M., Stingl, J., & Just, K. S. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04057-z · Cited by 3
“One of the reasons for this could be that liver-related complications often only occur in patients with cirrhosis as the overall mortality and the incidence of liver-specific com - plications increases parallel with the MASLD fibrosis stage [34 ].”
Cobbold, J., Miller, H., Hallsworth, K., Manousou, P., Marjot, T., Allison, M. E., Anstee, Q. M., Armstrong, M., Avery, L., Azzu, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00077-4 · Cited by 6
MASLD Beyond the Liver: A Systemic Driver of Cardiovascular, Renal, and Oncologic Risk
Liguori, A., Calvez, V., Petrucci, L., Termite, F., Tomasello, L., Sciarra, A., Varca, S., Gasbarrini, A., Pompili, M., & Miele, L. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00732-y · Cited by 3
Diagnosing and defining MASLD in people living with chronic hepatitis B
Martyn, E. M., Arenas‐Pinto, A., Gilson, R. J. C., Chandiwana, N. C., Flanagan, S., MacDonald, D. C., Tsochatzis, E. A., Venter, W. D., Manne‐Goehler, J., & Matthews, P. C. (2026) · Communications Medicine · doi:10.1038/s43856-026-01383-2 · Cited by 5
“2) 34,35 , irrespective of the presence or absence of CHB, although it is the severity of fi brosis rather than in fl ammation that is associated with long-term outcomes 36 .”
Jarvis, H., Brennan, P., Casanovas, T., Casler, K., Desai, M., Evans, P. H., Dillon, J. F., Grattagliano, I., Hallsworth, K., Hebditch, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00015-4 · Cited by 5
Расимовна, Х. А., Андреев, Д. Н., Maev, I. V., Kucheryavyy, Y. A., & Zaborovsky, A. V. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-221 · Cited by 3
Global multicenter validation of noninvasive fibrosis assessment pathways in MetALD and ALD
Gu, H., Díaz, L. A., Baeza, N., Idalsoaga, F. J., Zhou, X., Zheng, M., Maiwall, R., Sarin, S. K., Kulkarni, A. V., Ramyasri, R., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001020 · Cited by 3
Self-citationMolecular mechanisms and pathogenesis of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10529-0 · Cited by 10
“Advanced fibrosis, assessed histologically 229 or by non-invasive tests 230 , is strongly associated with adverse MASLD outcomes, including hepatic decompensation, HCC and liver-related mortality.”
Chayama, K., Hiramatsu, A., Shima, T., Itoh, Y., Yamaguchi, K., Nakajima, T., Hoshikawa, K. T., Kawamura, Y., Akuta, N., Ito, K., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13950 · Cited by 3
“17 More-over, a systematic review showed that NAFLD is associated with an increased risk of HCC and that the risk seemed to be limited to patients with cirrhosis.”
Backgroundda Rocha, K. V., Bueno, J. V. D. M., Neves, P. H. G., de Almeida, P. P. A. C., Bueno, A. C. D. M., Cabral, M. D., Gomes, G. M., & Vogas, K. B. (2023) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v9i8.10795 · Cited by 3
Yeh, M., Dai, C., Huang, C., Huang, S.-F. K., Tsai, P., Hsu, P., Huang, C., Wei, Y., Liang, P., Bair, M., et al. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12833 · Cited by 3
“7,19 One recent meta-analysis of five large-scale studies demonstrated that NASH patients with advanced fibrosis had a significantly greater risk of all-cause mortality and liver-related mortality than did NASH patients without fibrosis.”
BackgroundMichel, M. S., Funuyet‐Salas, J., Doll, M., Alqahtani, S. A., Armandi, A., Labenz, C., Galle, P. R., & Schattenberg, J. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-72105-8 · Cited by 4
“The presence of AF resembles an overall morbid phenotype with a high risk of several other hepatic-and extrahepatic complications, and high mortality 6 .”
BackgroundNovel dynamic and static biomarkers for the assessment of liver disease severity in MASLD
Amato, F., Marano, M., Gjini, K., VAIRA, L., Bugianesi, E., & Armandi, A. (2024) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.24.03186-9 · Cited by 4
Zhang, X., Liu, J., Wang, Q., Chen, H., Yan, Y., Xiang, X., Shen, S., & Feng, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1450049 · Cited by 4
“NAFLD has become one of the leading causes of chronic liver disease, signi fi cantly contributing to end-stage liver disease and the demand for liver transplantation, as well as increasing risks for hepatic cirrhosis, liver cancer, and cardiovascular diseases (2).”
Li, M., Yu, B., Zhang, X., Pan, J. B., Tang, L., Zhang, Y., Wang, R., Zeng, H., & Yang, S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1572853 · Cited by 5
Park, H., Yoon, E. L., Kim, M., Park, J.-H., Cheung, R. C., Cho, J.-Y., Kim, H., & Jun, D. W. (2025) · Scientific Reports · doi:10.1038/s41598-025-08434-z · Cited by 9
Kawahara, T., Toda, M., Kanagawa, M., Toyama, N., Suzuki, G., Kawahara, C., & Inazu, T. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s547088 · Cited by 4
“10–12 Therefore, improving liver function is as critical a therapeutic goal as glycemic control in patients with diabetes.”
Strengthening a Study of Diabetes Progression After Statin Use
Ganatra, R. B., Bhatnagar, A., & Herzig, S. J. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.8353 · Cited by 3
Indian Literature Review on Nonalcoholic Fatty Liver Disease
Balamurali, R., Murugesan, M., Shanmugam, C., Gopalsamy, S., & Chinnadurai, K. K. (2023) · Gastroenterology Hepatology and Endoscopy Practice · doi:10.4103/ghep.ghep_23_23 · Cited by 3
Lu, Y., Yu, B., Bu, Y., Lou, J., & Jin, Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1293336 · Cited by 3
“A considerable proportion of NASH patients may progress to cirrhosis, hepatocellular carcinoma, liver failure, or even death (3).”
BackgroundMetALD accounts for a large part of what we call MASLD!
Rudler, M., Bouzbib, C., & Thabut, D. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.023 · Cited by 3
Hasan, S., Brankovic, A., Awal, M. A., Rezaeieh, S. A., Keating, S. E., Abbosh, A. M., & Zamani, A. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3489626 · Cited by 3
Basile, A. O., Verma, A., Tang, L. A., Serper, M., Scanga, A. E., Farrell, A., Destin, B., Carr, R. M., Anyanwu‐Ofili, A., Rajagopal, G., et al. (2024) · Clinical and Translational Science · doi:10.1111/cts.70105 · Cited by 3
Askeland-Gjerde, D. E., Westlye, L. T., Andersson, P., Korbmacher, M., de Lange, A. G., van der Meer, D., Smeland, O. B., Halvorsen, S., Andreassen, O. A., & Gurholt, T. P. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100488 · Cited by 5
Balcar, L., Fromme, M., Kappe, N., Schaefer, B., Fraňková, S., Melkebeke, L. V., Stolk, J. N., Jachs, M., Semmler, G., Hofer, B., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101398 · Cited by 3
“AATD, alpha-1 antitrypsin de fi ciency; ALD, alcohol-associated liver disease; HCV hepatitis C virus; MASLD, metabolic dysfunction-associated steatotic liver disease; MetALD, metabolic ALD; SHR, subdistribution hazard ratio; SLD, steatotic liver disease. criteria.”
Lee, C. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.01.005 · Cited by 3
Gawrieh, S., Corey, K. E., Lake, J. E., Samala, N. R., Desai, A. P., Debroy, P., Sjoquist, J. A., Robison, M., Tann, M. A., Akisik, F. M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0279685 · Cited by 3
Self-citationHepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
Teng, M. L. P., Tan, D. J. H., Ng, C. H., & Huang, D. Q. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0069 · Cited by 4
Holzhey, M., Petroff, D., Wirkner, K., Engel, C., Baber, R., Tönjes, A., Zeynalova, S., Yahiaoui‐Doktor, M., Berg, T., Karlas, T., et al. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002656 · Cited by 3
Wiegand, J., Petroff, D., & Karlas, T. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12520 · Cited by 3
Semaglutide targets MASH molecular pathways beyond weight loss
Michel, M. S., & Schattenberg, J. M. (2025) · Nature Medicine · doi:10.1038/s41591-025-03927-w · Cited by 4
Gee, M. F. W., Palladino, A., Levy, H. R., Devol, E. B., & Kiaei, D. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117696 · Cited by 2
Bobo, J. F. G., Keith, B. A., Marsden, J. E., Zhang, J., & Schreiner, A. D. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.07.028 · Cited by 2
Chung, S. W., Park, M. K., Zhang, X., Wang, T., Jemielita, T., Fernandes, G. F., Engel, S. S., Jang, H., Lee, Y. B., Cho, E. J., et al. (2024) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2024/5667986 · Cited by 2
“Decompensated cirrhosis was defned as new onset of clinically obvious ascites, overt encephalopathy, or variceal hemorrhage [22].”
BackgroundNon-alcohlic Fatty Liver Disease (NAFLD): Is it a Dormant Volcano or Tip of an Iceberg?
Gupta, P. (2024) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_174_24 · Cited by 2
Liu, J., Oba, Y., Kondo, Y., Nakaki, R., & Yamano, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010144 · Cited by 2
What is new in the 2024 Chinese guidelines for fatty liver disease?
Yang, R., Wong, V. W., & Fan, J. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.1165 · Cited by 3
Li, N., Liu, C., Lu, Z., Wu, W., Zhang, F., Qiu, L., Shen, C., Sheng, D., & Liu, Z. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03598-4 · Cited by 2
Shaikh, O. S., Yan, P., & Butt, A. A. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100689 · Cited by 2
“14 Among patients with cirrhosis, we found an HCC incidence rate of 9.9 per 1000 person-years, whereas HCC incidence rate in noncirrhotic patients was 0.2 per 1000 person-years.”
InfluentialAffinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease
Balasubramani, S., Remih, K., Karl, A. S., Borchert, J., Schrader, C., Fromme, M., Kayatekin, C., Zhang, B., Levit, M. N., Krishnaswami, P., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70656 · Cited by 2
“Both measurements displayed a strong correlation ( r = 0.85, Figure S2C) and the PEA assessment yielded a somewhat higher AUROC for discriminating patients with versus without significant fibrosis (i.e., LSM ≥ 7.0 kPa vs. < 7.0 kPa; Figure S2D).”
InfluentialButt, N., Ali, S., Khemani, H., & Mumtaz, K. (2025) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v14.i3.105428 · Cited by 2
Jin, Y., Alissa, M., Ahmed, A. E., Al-Doaiss, A. A., Asiri, N., Assiri, Y., Khan, S. U., Khan, M. U., & Joseph, S. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103170 · Cited by 2
Roig, C. A., Romero, M., González, N., Pastrián, L. G., Lázaro, E. P., Grau, P. C., Barnó, M. A., Sánchez, A. G., Benítez, A. P., Serres-Gómez, M., et al. (2025) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2025.11545/2025 · Cited by 3
Liver fibrosis is associated with clinical and economic burden of cardiovascular disease in MASH
Corey, K. E., Mehta, A., Mangla, K. K., Chandramouli, A. S., Shoeb, A., Krarup, N., Augusto, M., Grau, K., Varma, S., & Bugianesi, E. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101621 · Cited by 2
“13 17 Previous studies have shown that patients with MASLD and advanced fibrosis (F3) have increased CV-related mortality rates compared with patients without advanced fibrosis.”
Practical Considerations for the Use of Semaglutide in MASH
Odenwald, M. A., & Rinella, M. E. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003816 · Cited by 2
Sato, S., Kawai, H., Yamaguchi, M., Nago, H., Kato, Y., Om, R., Terai, Y., Kita, Y., Ikeda, Y., Sato, S., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70136 · Cited by 2
“In particular, patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage 2 ≥ (F2), termed “at-risk” MASH, have a significantly increased risk of all-cause and liver-related mortality [5, 7].”
Novel insights into cyanobacterial (microcystins) neurotoxicity in rats: hepatic encephalopathy
Xu, W.-L., Chen, L., Fan, H.-H., Codd, G. A., Giesy, J. P., Guo, Y., Hilborn, E. D., Sedán, D., Andrinolo, D., Chatterjee, S., et al. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04219-5 · Cited by 3
“HE is an easily overlooked neurodegenerative disease, especially at its earlier stages, because pathogenesis of HE is complex and HE can be caused by multiple factors (Rose et al. 2020; Sanyal et al. 2021; Higuera-de-la-Tijera et al. 2023).”
Huang, X., Zhu, T., Li, S., Liu, T., Lin, S., Liang, H., Zhong, M., Sun, X., Chen, L., Bai, H., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001612 · Cited by 5
Metadata
- Authors
- Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., Wilson, L. A., Yates, K. P., Belt, P., Lazo, M., Kleiner, D. E., Behling, C., & Tonascia, J.
- Affiliations
- National Institutes of Health (US)
- From the Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); the Bloomberg School of Public Health, Johns Hopkins University, Baltimore (M.L.V.N., J.C., L.A.W., K.P.Y., P.B., M.L., J.T.), and the Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda (D.E.K.) — both in Maryland; Saint Louis University, St. Louis (B.A.N.-T.); Duke University, Durham, NC (A.M.D.); Cleveland Clinic, Cleveland (S.D.); the University of California, San Diego, School of Medicine, La Jolla (R.L., C.B.), and the University of California, San Francisco, School of Medicine, San Francisco (B.H.); Indiana University School of Medicine, Indianapolis (N.C.); and the Liver Institute Northwest, Seattle (K.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1559-1569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8881985
- OpenAlex
- W3206948891
- Cited by
- 1,146
- References
- 29
- Citations by year
- 2026: 215 · 2025: 270 · 2024: 266 · 2023: 236 · 2022: 153 · 2021: 3
- FWCI
- 118.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061713, U01DK061718, U01DK061728, U01DK061731)
- National Center for Advancing Translational Sciences (UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, liver fibrosis, all-cause mortality, liver complications, hepatic decompensation, variceal bleeding, ascites, hepatic encephalopathy, hepatocellular carcinoma, liver cirrhosis, bridging fibrosis, type 2 diabetes, estimated glomerular filtration rate, cardiac events, prognosis
- MeSH terms
- Adult, Biopsy, Female, Gastrointestinal Hemorrhage, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Prognosis, Prospective Studies, Severity of Illness Index, Incidence, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.